Immunocore has filed a patent for specific binding molecules, including T cell receptors (TCRs), that bind to a specific peptide derived from the HIV Gag gene product. These molecules have non-natural mutations that improve stability and yield while retaining their advantageous properties. They can be used in the development of immunotherapeutic reagents for the treatment of HIV-infected individuals. GlobalData’s report on Immunocore gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Immunocore, Peptide pharmacophores was a key innovation area identified from patents. Immunocore's grant share as of September 2023 was 30%. Grant share is based on the ratio of number of grants to total number of patents.
Specific binding molecule for treating hiv infection
A recently filed patent (Publication Number: US20230265191A1) describes a specific binding molecule that has the ability to bind to a specific sequence of amino acids (SLYNTVATL) when it is in complex with HLA-A*02. The binding molecule consists of a TCR alpha chain variable domain and a TCR beta chain variable domain. The patent claims that the alpha chain variable domain can have various amino acid sequences, including specific sequences mentioned in the claims.
The specific binding molecule described in the patent is an alpha-beta heterodimer, meaning it consists of an alpha chain TRAC constant domain and a beta chain TRBC1 or TRBC2 constant domain. The patent also mentions that the constant domain amino acid sequences of the alpha and beta chains can be modified by truncation or substitution to delete the native disulfide bond between certain cysteine residues.
The patent further claims that the specific binding molecule can be in single chain format, such as Va-L-Vß or Vß-L-Va, where Va and Vß represent TCR alpha and beta variable regions, Ca and Cß represent TCR alpha and beta constant regions, and L is a linker sequence. Additionally, the binding molecule can be associated with a detectable label, a therapeutic agent, or a PK modifying moiety.
The patent also describes the association of the specific binding molecule with an anti-CD3 antibody, which can be covalently linked to the C- or N-terminus of the TCR alpha or beta chain. The linkage can be achieved through a linker sequence, which can be selected from a group of specific sequences mentioned in the claims.
Furthermore, the patent includes a nucleic acid molecule encoding a TCR alpha chain and/or a TCR beta chain, where the TCR alpha chain can have various variable domain amino acid sequences.
The patent also mentions a pharmaceutical composition comprising the specific binding molecule, which can be used for treating HIV infection or AIDS in human subjects. The method involves administering a therapeutically effective amount of the specific binding molecule to the subject.
In summary, the patent describes a specific binding molecule that can bind to a specific amino acid sequence in complex with HLA-A*02. The molecule can have various amino acid sequences and can be modified to enhance its binding properties. It can be used in single chain format and can be associated with a detectable label, therapeutic agent, or PK modifying moiety. The binding molecule can also be linked to an anti-CD3 antibody and used for treating HIV infection or AIDS.
To know more about GlobalData’s detailed insights on Immunocore, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
